Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,080 GBX | 0.00% | +0.93% | +58.82% |
04-10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
04-10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Business Summary
Number of employees: 78
Sales per Business
GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Synthetic DNA and RNA Products
92.5
%
| 0 | 95.0 % | 0 | 92.5 % | -22.74% |
Licences and Royalties
7.5
%
| 0 | 5.0 % | 0 | 7.5 % | +17.65% |
Sales per region
GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
60.4
%
| 0 | 69.5 % | 0 | 60.4 % | -31.06% |
Europe
31.7
%
| 0 | 24.3 % | 0 | 31.7 % | +3.66% |
Rest of World
7.8
%
| 0 | 6.2 % | 0 | 7.8 % | 0.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 47 | 21/12/20 |
David John Roth
DFI | Director of Finance/CFO | 56 | 21/12/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 21/12/20 |
Director/Board Member | 53 | - | |
Chairman | 68 | 21/12/20 | |
Heikki Lanckriet
CEO | Chief Executive Officer | 47 | 21/12/20 |
Director/Board Member | 55 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,805,208 | 3,893,037 ( 30.40 %) | 0 | 30.40 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+58.82% | 174M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- 4BB Stock
- Company 4basebio PLC